OncoMed pullback a buying opportunity, says Piper Jaffray Piper Jaffray believes the pullback in shares of OncoMed provides an attractive entry point into the name ahead of additional clinical data readouts in June. The reiterates an Overweight rating on the stock with a $48 price target.
OncoMed receives orphan status for tarextumab as pancreatic cancer treatment The FDA granted OncoMed orphan status for tarextumab, as a treatment for pancreatic cancer. Note that earlier the FDA also granted the drug orphan status as a treatment for small cell lung cancer. Reference Link